News

Artelo Biosciences Advances ART27.13 with Patent Allowance

Artelo Biosciences Advances ART27.13 with Patent Allowance

Key Development for Artelo Biosciences

Artelo Biosciences, Inc., a pioneering pharmaceutical company focused on innovative therapeutic solutions, recently garnered significant recognition as it received a Notice of Allowance from the European Patent Office (EPO). This approval is associated with their European patent application No. 21827629.3, targeting the intended commercial formulation of ART27.13.

The Importance of Patent Protection

This patent covers crucial compositions of ART27.13, which is currently being evaluated as a therapeutic option for cancer-related anorexia. By extending patent protection, potentially through December 2041, Artelo is enhancing its intellectual property strategy, ensuring the long-term viability and commercial potential of ART27.13.

Addressing Cancer-Related Anorexia

ART27.13 is designed to tackle the challenges of cancer-related anorexia, a condition impacting over 60% of advanced-stage cancer patients. Notably, there are currently no approved treatments in regions like the US and EU for this condition. CEO Gregory D. Gorgas emphasized the potential of ART27.13 to offer a first-in-class solution tailored for these patients.

Clinical Trials and Evaluation

The drug is under evaluation in the Phase 2 CAReS clinical trial, examining its effectiveness in reversing weight loss among cancer patients. Preliminary results from previous studies indicate that the drug was well tolerated and showed strength in stabilizing or reversing weight loss in a notable portion of participants. The Phase 2 results are expected to unveil during the third quarter of 2025.

The Science Behind ART27.13

Developed originally by AstraZeneca, ART27.13 is a groundbreaking benzimidazole derivative, administered orally once daily. It selectively targets peripheral cannabinoid receptors CB1 and CB2, with promising applications in improving appetite and combating muscle degeneration, ultimately enhancing the quality of life for cancer patients.

Clinical Findings and Future Potential

Over 250 participants have already been involved in six clinical studies, where ART27.13 has demonstrated its ability to significantly improve body weight among healthy individuals with back pain. Importantly, ART27.13 aims to achieve systemic metabolic benefits while minimizing adverse effects typically associated with central nervous system interactions.

Understanding the CAReS Study

The Cancer Appetite Recovery Study (CAReS) is pivotal for exploring ART27.13's potential as a treatment for those suffering from cancer-related weight loss. The study is structured to assess the drug’s effectiveness in increasing lean body mass and appetite—integral factors in enhancing patient recovery and comfort during cancer treatment.

Challenges of Cancer-Related Anorexia

Patients dealing with cancer often face the distressing issue of anorexia, leading to adverse health outcomes and weakened immunity. A weight loss exceeding 5% in these patients can be indicative of poor prognoses, stressing the need for effective interventions like ART27.13.

About Artelo Biosciences

Artelo Biosciences is dedicated to developing therapeutics that modulate lipid-signaling pathways, aiming to meet significant clinical needs across various conditions such as cancer, anxiety, and chronic pain. Alongside its therapeutic efforts, the company is innovating in finance by designating Solana as a core reserve asset, leveraging blockchain technology to diversify its financial strategies and enhance shareholder value.

Contact Information

For further inquiries, please reach out to Crescendo Communications, LLC, at 212-671-1020 or via email at ARTL@crescendo-ir.com.

Frequently Asked Questions

What is the focus of Artelo Biosciences?

Artelo Biosciences focuses on developing therapeutics that modulate lipid-signaling pathways for conditions like cancer and pain management.

What is ART27.13?

ART27.13 is a cannabinoid agonist being evaluated as a treatment for cancer-related anorexia.

Why is the patent allowance important?

The patent allowance secures the commercial potential of ART27.13 and protects the formulation against competition.

What is the CAReS clinical trial?

The CAReS clinical trial is a Phase 1/2 study evaluating the efficacy of ART27.13 in patients suffering from cancer-related anorexia.

How can I stay updated on Artelo’s progress?

Stay informed by visiting Artelo’s official website or following their announcements on their social media platforms.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 62

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 133

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 107

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 20

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 18

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 48

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 164

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 147

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 59

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading

Top 5 Most Recently Viewed Articles

First Horizon Taps Kevin Piker to Boost Acadiana Ties

Updated Category News Views 22

Kevin Piker Joins First Horizon: A Strategic Move First Horizon Bank just made a move that's got tongues wagging in the banking world: they've roped in Kevin Piker as a Commercial Relationship Manager, specifically targeting the Acadiana market. Why's this a big deal, you ask? Well, this guy's got over 25 years in the trenches of banking and commercial lending, and he's...

Continue Reading
Tesla and Samsung's $2 Billion Energy Storage Partnership

Updated Category News Views 186

Tesla's Strategic Energy Storage Initiative Tesla Inc. (NASDAQ: TSLA) has taken a significant step forward by striking a $2 billion deal with Samsung SDI, a leading manufacturer in the energy storage technology sector. This agreement underscores Tesla's commitment to advancing its energy storage solutions, an area experiencing substantial growth in recent times. $2...

Continue Reading
Unlocking Business Growth: A New Mindset for Entrepreneurs

Updated Category News Views 267

Unlocking Business Growth: A New Mindset for Entrepreneurs As the years pass and entrepreneurs look for strategies to achieve success, business growth strategist and author Chad Smith warns against a damaging mindset. Many believe that waiting for the new year is the key to rejuvenating their business. However, Smith argues that this is a myth that can hinder progress....

Continue Reading
Exciting Merger Announcement: Cornerstone and Plumas Join Forces

Updated Category News Views 145

Strategic Merger Between Cornerstone and Plumas Bancorp Cornerstone Community Bancorp and Plumas Bancorp have recently made headlines with the shareholder approval for their merger. This significant step unites two reputable banking institutions, enhancing their capabilities and services offered to their customers. The merger will combine Cornerstone with Plumas,...

Continue Reading
Smart Investment Moves for Growing Companies in California

Updated Category Business Views 87

Smart Investment Moves for Growing Companies in California Growing a company in California can be exciting, but it can also become expensive very quickly. The state offers access to huge markets, strong tech networks, and a large pool of skilled workers. Many business owners see the Golden State as the perfect place to expand. Still, growth comes with pressure. Rent is...

Continue Reading